Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet

被引:28
作者
Cleland, John G. F. [1 ]
Coletta, Alison P. [1 ]
Clark, Andrew L. [1 ]
机构
[1] Univ Hull, Dept Cardiol, Castle Hill Hosp, Kingston Upon Hull HU16 5JQ, Yorks, England
关键词
randomised controlled trials; heart failure;
D O I
10.1016/j.ejheart.2007.04.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at the American College of Cardiology meeting in March 2007. Unpublished reports should be considered as preliminary data, as analyses may change in the final publication. The ALPHA study suggested that patients with heart failure (HF) due to idiopathic dilated cardiomyopathy who have a negative T-wave alternans test have a good prognosis and are unlikely to benefit from ICD therapy. EVEREST provides some evidence of short-term symptom benefit of tolvaptan in patients with acute decompensated HF but no clinically important long-term benefit. FUSION II failed to show a benefit of nesiritide in patients with chronic decompensated HE Reducing blood pressure in hypertensive patients improved diastolic dysfunction in VALIDD. Eplerenone did not improve left ventricular remodelling in mild to moderate chronic HE Selecting HF patients for revascularisation using FDG-PET imaging did not significantly improve outcome. Crataegus extract added to standard HF therapy did not reduce morbidity or mortality in SPICE. The COURAGE study, conducted in patients without HF or major cardiac dysfunction, showed that PCI did not reduce cardiac morbidity or mortality and can be safely deferred in patients with stable coronary disease on optimal medical therapy. The COACH study failed to show that HF nurse-intervention could reduce hospitalisations but did show trends to lower mortality, especially amongst patients with reduced ejection fraction; however, the smaller REMADHE study suggested striking benefits on morbidity and mortality. A large study of BNP provided additional information on its ability to distinguish cardiac and pulmonary breathlessness. The importance of dietary intervention in post-MI patients was highlighted by the findings of THIS-diet study. (C) 2007 European Society of Cardiology. Published by Elsevier B.V All rights reserved.
引用
收藏
页码:740 / 745
页数:6
相关论文
共 22 条
  • [1] Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The Cardiovascular Health Study
    Aurigemma, GP
    Gottdiener, JS
    Shemanski, L
    Gardin, J
    Kitzman, D
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (04) : 1042 - 1048
  • [2] BODEN WE, 2007, N ENGL J MED 0326
  • [3] Chamberlain DA, 1997, LANCET, V350, P461
  • [4] CLARK RA, 2007, BMJ 0410
  • [5] Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death - The trans-European network-home-care management system (TEN-HMS) study
    Cleland, JGF
    Louis, AA
    Rigby, AS
    Janssens, U
    Balk, AHMM
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (10) : 1654 - 1664
  • [6] The heart failure revascularisation trial (HEART): rationale, design and methodology
    Cleland, JGF
    Freemantle, N
    Ball, SG
    Bonser, RS
    Camici, P
    Chattopadhyay, S
    Dutka, D
    Eastaugh, J
    Hampton, J
    Large, S
    Norell, MS
    Pennell, DJ
    Pepper, J
    Sanda, S
    Senior, R
    Smith, D
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2003, 5 (03) : 295 - 303
  • [7] Clinical trials update from the American Heart Association 2006: OAT, SALT 1 and 2, MAGIC, ABCD, PABA-CHF, IMPROVE-CHF, and percutaneous mitral annuloplasty
    Cleland, John G. F.
    Coletta, Alison P.
    Abdellah, Ahmed Tageldien
    Nasir, Mansoor
    Hobson, Neil
    Freemantle, Nick
    Clark, Andrew L.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2007, 9 (01) : 92 - 97
  • [8] Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM
    Coletta, AP
    Cleland, JGF
    Freemantle, N
    Loh, H
    Memon, A
    Clark, AL
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2003, 5 (05) : 697 - 704
  • [9] Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome Study with Tolvaptan (EVEREST)
    Gheorghiade, M
    Orlandi, C
    Burnett, JC
    Demets, D
    Grinfeld, L
    Maggioni, A
    Swedberg, K
    Udelson, JE
    Zannad, F
    Zimmer, C
    Konstam, MA
    [J]. JOURNAL OF CARDIAC FAILURE, 2005, 11 (04) : 260 - 269
  • [10] Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure - A randomized controlled trial
    Gheorghiade, M
    Gattis, WA
    O'Connor, CM
    Adams, KF
    Elkayam, U
    Barbagelata, A
    Ghali, JK
    Benza, RL
    McGrew, FA
    Klapholz, M
    Ouyang, J
    Orlandi, C
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (16): : 1963 - 1971